CN113811539A - 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 - Google Patents

蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 Download PDF

Info

Publication number
CN113811539A
CN113811539A CN202080014248.7A CN202080014248A CN113811539A CN 113811539 A CN113811539 A CN 113811539A CN 202080014248 A CN202080014248 A CN 202080014248A CN 113811539 A CN113811539 A CN 113811539A
Authority
CN
China
Prior art keywords
degrees
theta
crystalline
peaks
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080014248.7A
Other languages
English (en)
Chinese (zh)
Inventor
林虹
李群
马克·安德雷斯
张化平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pruder Therapeutics Ltd
Original Assignee
Pruder Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pruder Therapeutics Ltd filed Critical Pruder Therapeutics Ltd
Publication of CN113811539A publication Critical patent/CN113811539A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN202080014248.7A 2019-02-13 2020-02-13 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 Pending CN113811539A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962805175P 2019-02-13 2019-02-13
US62/805,175 2019-02-13
US201962805726P 2019-02-14 2019-02-14
US62/805,726 2019-02-14
PCT/US2020/018185 WO2020168125A1 (en) 2019-02-13 2020-02-13 Selective inhibitor of protein arginine methyltransferase 5 (prmt5)

Publications (1)

Publication Number Publication Date
CN113811539A true CN113811539A (zh) 2021-12-17

Family

ID=69845552

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080014248.7A Pending CN113811539A (zh) 2019-02-13 2020-02-13 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂

Country Status (12)

Country Link
US (1) US20220160713A1 (cg-RX-API-DMAC10.html)
EP (1) EP3924360A1 (cg-RX-API-DMAC10.html)
JP (1) JP2022521491A (cg-RX-API-DMAC10.html)
KR (1) KR20210129051A (cg-RX-API-DMAC10.html)
CN (1) CN113811539A (cg-RX-API-DMAC10.html)
AU (1) AU2020223058A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021015796A2 (cg-RX-API-DMAC10.html)
CA (1) CA3129612A1 (cg-RX-API-DMAC10.html)
IL (1) IL285536A (cg-RX-API-DMAC10.html)
MX (1) MX2021009796A (cg-RX-API-DMAC10.html)
WO (1) WO2020168125A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202105887B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677B (zh) 2020-07-31 2026-07-28 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
US20220251088A1 (en) * 2020-12-10 2022-08-11 Prelude Therapeutics, Incorporated Processes for Making PRMT5 Inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044576A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
CN107530347A (zh) * 2015-03-27 2018-01-02 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的共结晶体
US20180243328A1 (en) * 2015-08-26 2018-08-30 Janssen Pharmaceutica Nv Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
US20190048014A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EA031895B1 (ru) * 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044576A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
CN107530347A (zh) * 2015-03-27 2018-01-02 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的共结晶体
US20180243328A1 (en) * 2015-08-26 2018-08-30 Janssen Pharmaceutica Nv Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
US20190048014A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
CN111527099A (zh) * 2017-08-09 2020-08-11 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
许晓双,等: "蛋白质精氨酸甲基转移酶抑制剂的研究进展", 江苏医药, no. 09, 30 September 2018 (2018-09-30), pages 98 - 101 *
魏野,等: "蛋白质精氨酸甲基转移酶5对人卵巢癌HO8910细胞增殖能力的影响", 医学研究生学报, vol. 02, no. 06, 15 June 2018 (2018-06-15), pages 11 - 18 *

Also Published As

Publication number Publication date
KR20210129051A (ko) 2021-10-27
IL285536A (en) 2021-09-30
ZA202105887B (en) 2024-12-18
AU2020223058A1 (en) 2021-09-09
BR112021015796A2 (pt) 2021-10-13
CA3129612A1 (en) 2020-08-20
JP2022521491A (ja) 2022-04-08
US20220160713A1 (en) 2022-05-26
WO2020168125A1 (en) 2020-08-20
EP3924360A1 (en) 2021-12-22
MX2021009796A (es) 2021-09-08

Similar Documents

Publication Publication Date Title
US11208416B2 (en) Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
JP7328218B2 (ja) タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤
US20220160713A1 (en) Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
CN114829370B (zh) 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
WO2023178547A1 (en) Polymorphic compounds and uses thereof
EA043295B1 (ru) Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5)
HK40067540A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US20240352029A1 (en) CDK Inhibitors And Their Use As Pharmaceuticals
HK40031042A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
HK40031042B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211217